Abstract book 6th RMS 16.indd

Methods: Urine samples were collected
from individuals with history of dark
urine and from all their family members.
Diagnosis was made by observing
changing in urine colour after prolonged
standing of samples, and by adding ferric
chloride (FeCL3). Confirmation of diagnosis
was done by measuring the levels of
homogentisic acid. Signs and symptoms
were assessed by performing clinical
examination. Radiological examination
was performed to assess the progression
and complications of the disease using
x-ray, ultrasound, CT-scan, and MRI.
Results: Preliminary results have
identified 60 cases of AKU (age range,
1-60 years). The clinical, biochemical and
genetic findings will be presented. Five
novel mutations have been identified in
Jordanian population.
Conclusion: The prevalence of AKU is likely
to be high in Jordan due to the high rate of
consanguineous marriages. Furthermore,
AKU should be in mind of physicians when
evaluating patients with history of dark
urine and low back pain.
375
Prevalence of Meropenem
Susceptibilty among Gram Negative
Pathogens Isolated from Intensive
Care Units in Jordan
Naheel Haloub MD*, Jamal Wadi, Mais Al
Ahmad, Amani Samara, Amani Romman
* Head of Microbiology Dep. Specialty
hospital, Amman Jordan
falakqadery@specialty-hospital.com
Objectives: Meropenem is a relatively new
carbapenem in some Middle East countries;
our aim is to evaluate its susceptibility in
gram-negative pathogens isolated from
ICU patients and to identify the prevalence
of ICU bacterial isolates identified as
pathogens based on CDC-NHSN definition
for pathogens in the affected organs
Methods:
Results: One-hundred and seventy-three
gram-negative pathogens were reviewed
for susceptibilities and ESBL production.
E. coli was a dominant pathogen followed
by Klebsiella, and Pseudomonas. ESBLproduction
was in E. coli (62.7%) and
Klebsiella (58.6%), considering all gramnegative
bacilli studied; ESBL rates were
30.7%. Both Meropnem and Imipenem
showed superior activity against gramnegative
pathogens. Meropenem did better
than imipenem against pseudomonas
species, but PIP/TAZ did better than both
carbapenems (p = 0.02). The difference
in susceptibility patterns among ESBLproducing
pathogens compared with
same non-ESBL producers species showed
that carbapenems were superior to other
classes of antibacterials tested in this
regard, and rates of resistant ESBL to both
carbapenems were 5.6%; trustworthy
in the initial empiric therapy in ICUs and
hospitals that suffer from high rates of
ESBL-producers. While PIP/TAZ showed
highly significant difference (p < 0.0001)
in activity against ESBL and non-ESBL
producers
Conclusion: Meropenem and imipenem
are trustworthy in the initial empiric
therapy. Gram-negative pathogens are
highly susceptibility to both carbapenems,
and benefit extends to ICUs with high
rates of ESBL-producers.
376
Snapshot on Molecular Genetic
Pathology Updates
Rame Khasawneh MD, Pathology Specialist,
King Hussein Medical Center (Jordan)
dr.r.khasawneh@gmail.com
Objectives: This presentation highlight and
emphasis on the most important updates
in molecular oncology and genetics with
relevant and clear clinical utility.
Methods: Online resources including
journals, webinars, and different genetic
committee guidelines were reviewed.
Results: Molecular genetics pathology is
an emerging field of pathology; simply it
implies medicine under submicroscopic
level through studying human biomarkers
that aid in elucidating disease etiology
and pathogenesis, help in diagnosis,
set prognostic stratifications and most
importantly pave the road for applying
personalized medicine through targeted
and tailored therapeutic options.
Conclusion: Molecular genetics
pathology is a fast pace specialty where
at least a weekly updates is a mandatory
to catch up important updates, new
guidelines and recommendations in
www.jrms.gov.jo
186